GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Intelligent Bio Solutions Inc (NAS:INBS) » Definitions » Return-on-Tangible-Asset

INBS (Intelligent Bio Solutions) Return-on-Tangible-Asset : -192.69% (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Intelligent Bio Solutions Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Intelligent Bio Solutions's annualized Net Income for the quarter that ended in Mar. 2025 was $-10.18 Mil. Intelligent Bio Solutions's average total tangible assets for the quarter that ended in Mar. 2025 was $5.28 Mil. Therefore, Intelligent Bio Solutions's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was -192.69%.

The historical rank and industry rank for Intelligent Bio Solutions's Return-on-Tangible-Asset or its related term are showing as below:

INBS' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -317.42   Med: -131.72   Max: -48.56
Current: -129.12

During the past 8 years, Intelligent Bio Solutions's highest Return-on-Tangible-Asset was -48.56%. The lowest was -317.42%. And the median was -131.72%.

INBS's Return-on-Tangible-Asset is ranked worse than
91.69% of 866 companies
in the Medical Devices & Instruments industry
Industry Median: -0.995 vs INBS: -129.12

Intelligent Bio Solutions Return-on-Tangible-Asset Historical Data

The historical data trend for Intelligent Bio Solutions's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelligent Bio Solutions Return-on-Tangible-Asset Chart

Intelligent Bio Solutions Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Return-on-Tangible-Asset
Get a 7-Day Free Trial -131.72 -57.83 -48.56 -121.84 -140.03

Intelligent Bio Solutions Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -145.14 -101.92 -128.42 -148.61 -192.69

Competitive Comparison of Intelligent Bio Solutions's Return-on-Tangible-Asset

For the Medical Devices subindustry, Intelligent Bio Solutions's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intelligent Bio Solutions's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Intelligent Bio Solutions's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Intelligent Bio Solutions's Return-on-Tangible-Asset falls into.


;
;

Intelligent Bio Solutions Return-on-Tangible-Asset Calculation

Intelligent Bio Solutions's annualized Return-on-Tangible-Asset for the fiscal year that ended in Jun. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Jun. 2024 )  (A: Jun. 2023 )(A: Jun. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Jun. 2024 )  (A: Jun. 2023 )(A: Jun. 2024 )
=-10.157/( (5.1+9.407)/ 2 )
=-10.157/7.2535
=-140.03 %

Intelligent Bio Solutions's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=-10.176/( (4.781+5.781)/ 2 )
=-10.176/5.281
=-192.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


Intelligent Bio Solutions  (NAS:INBS) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Intelligent Bio Solutions Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Intelligent Bio Solutions's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Intelligent Bio Solutions Business Description

Traded in Other Exchanges
N/A
Address
135 West, 41ST Street, 5th Floor, New York, NY, USA, 10036
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).
Executives
Harry Simeonidis director, officer: CEO, President 708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Foundation Ma-ran 10 percent owner 1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
Gary W. Rollins Foundation 10 percent owner 1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
David A Jenkins director P.O. BOX 682838, PARK CITY UT 84068
Jason Isenberg director 1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
Spiro Kevin Sakiris officer: Chief Financial Officer 708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Life Science Biosensor Diagnostics Pty Ltd 10 percent owner LEVEL 9, 85 CASTLEREAGH STREET, SYDNEY C3 2000
Tom Parmakellis director 708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Victoria Gavrilenko director 708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
Christopher Towers director 1981 MARCUS AVENUE, SUITE 130, LAKE SUCCESS NY 11042
Lawrence B Fisher director C/0 FINANCIAL FEDERAL CORP, 733 THIRD AVENUE, NEW YORK NY 10017
Leonard Victor Kempler director 708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
George Margelis director 708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Boyages Steven Constantine director 708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
Jonathan Scott Hurd director 708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017